These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33889929)

  • 1. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
    Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
    Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
    Li W; Wertheimer A
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
    [No Abstract]   [Full Text] [Related]  

  • 5. The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Diak IL; Swank K; McCartan K; Beganovic M; Kidd J; Gada N; Kapoor R; Wolf L; Kangas L; Wyeth J; Salvatore T; Fanari M; LeBoeuf AA; Mishra P; Blum MD; Dal Pan G
    Drug Saf; 2023 Feb; 46(2):145-155. PubMed ID: 36460854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
    Isles M
    Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolones: A hot topic for pharmacists and the Food and Drug Administration's Division of Drug Information.
    Molnar DM; Kremzner ME
    J Am Pharm Assoc (2003); 2019; 59(1):13-16. PubMed ID: 30348510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of outsourcing facilities in overcoming drug shortages.
    Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e110-e114. PubMed ID: 32943335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending the US Food and Drug Administration's Postmarket Authorities.
    Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
    JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug events and the Freedom of Information Act: an apple in Eden.
    Stang PE; Fox JL
    Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: AN UNSPOKEN OPPORTUNITY FOR PHARMACISTS.
    Parks KC; Bernard B; Cogdill CB
    Int J Pharm Compd; 2015; 19(5):377-80. PubMed ID: 26775444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.